Spravato treatment for Jupiter — REMS-certified, insurance-covered TRD care.

RECO Integrated Psychiatry's Delray Beach office is the closest REMS-certified Spravato site for most of Jupiter — 32 miles south, roughly 45 minutes on I-95 outside of rush. The psychiatry team manages the concurrent oral antidepressant, insurance prior authorization, and PHQ-9 tracking under one roof, so clients from Abacoa or Tequesta are not shuttling between an infusion center, a prescriber, and a records office. Coverage is in network with Florida Blue, Aetna, Cigna, UnitedHealthcare, Humana, and BCBS.

Jupiter sits 32 miles north of RECO Integrated Psychiatry’s Delray Beach campus — roughly 45 minutes down I-95 outside of morning and evening rush. For adults in Abacoa, Tequesta, Jupiter Inlet Colony, Admirals Cove, or Jonathan’s Landing who have exhausted two or more adequate trials of oral antidepressants without meaningful PHQ-9 improvement, esketamine is often the next evidence-based step. RECO’s Delray office is the closest REMS-certified Spravato treatment site for most of northern Palm Beach County, and the psychiatry, nursing, and prior-authorization work all happen under one roof.

Spravato and the REMS protocol — what treatment actually looks like

Esketamine is delivered as a nasal spray, self-administered by the client under the direct supervision of a treating nurse. Standard TRD induction dosing is 56 mg for session one and 84 mg from session two forward, with adjustments made downward for tolerability rather than upward. The device is a single-use nasal applicator, and sessions are booked in a dedicated Spravato suite rather than a general infusion room.

Every session includes two hours of post-dose monitoring under the FDA-mandated Risk Evaluation and Mitigation Strategy (REMS). Blood pressure is checked at baseline, at 40 minutes when transient elevation typically peaks, and at 90 minutes; dissociative symptoms are quantified with the Clinician-Administered Dissociative States Scale (CADSS); sedation is tracked on the Modified Observer’s Assessment of Alertness/Sedation. Clients cannot drive after the session — a ride home is confirmed before every dose.

REMS prescriber enrollment, per-session monitoring documentation, and pharmacy coordination are handled internally. Clients arriving from Jupiter do not need to coordinate with an outside infusion center or a separate prescriber — the psychiatrist, the Spravato nurse, and the admissions team share the same chart.

The induction and maintenance schedule

For treatment-resistant depression, induction runs twice weekly for four weeks — eight sessions total — followed by weekly dosing in weeks five through eight, then every one to two weeks for maintenance based on PHQ-9 response and clinical judgment. For the major depressive disorder with acute suicidal ideation indication, the protocol is twice weekly for four weeks with a separate maintenance decision at week five.

Most clients report some perceptible shift within the first week; a durable antidepressant response typically consolidates across the eight-session induction. If PHQ-9 has not moved meaningfully by session six, the psychiatrist re-evaluates rather than continuing on autopilot — a non-responder is a signal to reconsider the concurrent oral antidepressant, the working diagnosis, or the presence of comorbid conditions like bipolar II or PTSD that change the treatment plan.

Discontinuation is done on a taper, not abruptly. Maintenance is stepped down from weekly to every two weeks, then every three, then monthly, with PHQ-9 tracked at each visit and the oral antidepressant continued through the wean.

Spravato with an oral antidepressant, not instead of one

The FDA approval for esketamine is specifically for use in conjunction with an oral antidepressant — it is not approved as monotherapy. Clients arriving on a partial-response SSRI such as sertraline or escitalopram, or an SNRI such as venlafaxine or duloxetine, typically continue that medication throughout Spravato treatment. Stopping the oral agent to start esketamine is not the protocol and is not covered by the labeling.

Clients who have failed multiple prior antidepressants may start or switch an oral agent at the same time as beginning esketamine. Common concurrent choices include an SNRI paired with a modest augmenting dose of aripiprazole or quetiapine, or lithium augmentation where the history supports it. The RECO psychiatry team manages the concurrent medication as part of the treatment plan — the Spravato nurse does not prescribe in isolation.

For clients with a long medication history — three, four, or more prior trials — the intake includes a formal review of prior adequacy (dose, duration, and response) so that the concurrent oral agent is chosen deliberately rather than defaulted to whatever was last prescribed.

Spravato versus IV ketamine — how we choose

Spravato and IV ketamine are related but not interchangeable. Esketamine — the S-enantiomer of ketamine — delivered nasally is FDA-approved for TRD and for MDD with acute suicidal ideation, and is covered by most commercial insurance plans for documented treatment-resistant depression. Racemic IV ketamine is off-label for depression, typically cash-pay, and dosed by weight and clinical response rather than in fixed increments.

Spravato dosing is fixed at 56 mg or 84 mg per session; IV ketamine allows finer titration. End-to-end time in the office is comparable — both run roughly two hours, with the IV infusion itself lasting about 40 minutes and Spravato requiring the two-hour REMS monitoring window. The trade-offs are real: Spravato wins on insurance coverage and regulatory oversight; IV ketamine offers dosing flexibility and, for some clients, a different subjective profile.

At the initial consult, the psychiatry team walks through both options given the client’s insurance, prior treatment history, and schedule. For most Jupiter clients arriving with a Florida Blue, Aetna, Cigna, UnitedHealthcare, or Humana plan and a documented history of two or more failed antidepressant trials, Spravato is the covered first-line interventional option.

What to expect on your first visit from Jupiter

The first appointment is a 60-90 minute psychiatric evaluation with the treating psychiatrist — it is not a Spravato dose. Prior treatment history is reviewed in detail, PHQ-9 and GAD-7 are administered at baseline, and screens are run for bipolar spectrum and PTSD, both of which change the treatment plan. If Spravato is appropriate, the office begins insurance prior authorization the same day; the first dosing session is typically scheduled within one to two weeks depending on payer turnaround.

Clients from Abacoa or Tequesta should plan for a 45-minute drive each way and clear the day for dose one — the two-hour monitoring window plus travel means a morning appointment finishes by early afternoon. The office confirms ride-home logistics before the first session; clients drive themselves to the appointment, but do not drive home.

Insurance and admissions from Jupiter

RECO Integrated Psychiatry is in network with Florida Blue, Aetna, Cigna, UnitedHealthcare, Humana, and BCBS for psychiatric services, and Spravato is covered under these plans for documented treatment-resistant depression. Prior authorization requires documentation of two or more adequate prior trials of oral antidepressants — adequate meaning a therapeutic dose held for at least six weeks. The admissions team compiles this from outside records so clients do not have to.

Out-of-pocket cost after coverage varies by plan tier and deductible status. A written benefits verification is provided before the first dose so clients from Jupiter are not surprised at the counter.

Serving residents of: Abacoa, Jupiter Inlet Colony, Tequesta, Admirals Cove, Jonathan's Landing.